Tag: Incyte
Incyte’s Ruxolitinib Cream demonstrates promising efficacy in TRuE-AD3 study
Incyte (Nasdaq:INCY), an esteemed biopharmaceutical giant, has unveiled compelling expanded findings from its Phase 3 TRuE-AD3 study on the ruxolitinib cream (Opzelura) for treating children ... Read More
Incyte bags Opzelura EC approval for treatment of non-segmental vitiligo
Incyte has secured marketing authorization for Opzelura (ruxolitinib) cream 15mg/g from the European Commission (EC) for non-segmental vitiligo with facial involvement in adults and adolescents, ... Read More
US biopharma company Incyte bags Opzelura FDA approval for vitiligo
Opzelura FDA approval for vitiligo : Incyte has secured approval for Opzelura (ruxolitinib) cream 1.5% from the US Food and Drug Administration (FDA) for the ... Read More
BriaCell Therapeutics’ Bria-IMT gets FDA fast track status in breast cancer
BriaCell Therapeutics has secured the fast track status from the US Food and Drug Administration (FDA) for its lead candidate — Bria-IMT for the treatment ... Read More
Lilly Covid drug trial : US pharma giant launches phase 3 trial of baricitinib
Lilly Covid drug trial : Eli Lilly and Company has enrolled the first patient in a phase 3 randomized, double-blind, placebo-controlled trial to assess the ... Read More
Innovent Biologics begins parsaclisib phase 2 trial in follicular lymphoma
Innovent Biologics has dosed the first patient in a phase 2 trial of parsaclisib (IBI-376), a novel and selective PI3Kδ inhibitor in follicular lymphoma (FL). ... Read More
Incyte bags Pemazyre FDA approval for cholangiocarcinoma treatment
Pemazyre FDA approval : US biopharma company Incyte has bagged accelerated approval from the US Food and Drug Administration (FDA) for Pemazyre (pemigatinib) for the ... Read More
Incyte to launch ruxolitinib coronavirus clinical trial in US
Ruxolitinib coronavirus clinical trial : Incyte revealed that it is working with the US Food and Drug Administration (FDA) to launch the phase 3 RUXCOVID ... Read More
Incyte secures FDA priority review for pemigatinib in cholangiocarcinoma
Delaware-based pharma company Incyte has secured priority review for pemigatinib from the US Food and Drug Administration (FDA) for the treatment of locally advanced or ... Read More
Incyte, Innovent announce collaboration for three cancer drugs in China
US pharma company Incyte and Chinese biopharma company Innovent Biologics through their respective subsidiaries have entered into a deal worth up to $391.5 million for ... Read More